The mechanisms that lead to loss of MHC class I expression in different types of tumors are not yet fully known. Accordingly, we studied colorectal carcinomas to elucidate the specific mechanisms of evasion of the T-cell immune response. We selected tumors with total loss of MHC class I expression and studied 124 colorectal carcinomas with immunohistochemical staining and anti-HLA monoclonal antibodies (mAb). Fourteen of 124 (11%) tumors exhibited a phenotype with HLA class I total loss. Microsatellite instability (MSI) analysis was also carried out in the same tumor samples. The expression of b 2 -microglobulin (b 2 m), HLA-A, B, and C antigens, transporter associated with antigen processing 1 (TAP1), TAP2, low-molecular-weight protein 2 (LMP2), and LMP7 were analyzed using reverse-transcription polymerase chain reaction (RT-PCR) in microdissected tumor samples. Four of 14 microsatellite instability-positive (MSI þ ) and W6/32 mAb-negative tumors showed biallelic inactivation of b 2 m and accumulation of HLA class I heavy chain in the cytoplasm. MSI-negative (MSI -)/W6/32 mAb-negative tumors presented alterations in the expression of components of the antigen processing machinery (APM). Nine of 10 tumor samples showed LMP7 gene downregulation, and four of 10 presented TAP2 dysregulation. This group apparently expressed normal levels of heavy chain and b 2 m mRNA. Two major mechanisms in colorectal cancer appear to be responsible for the total loss of MHC surface expression (b 2 m mutations and LMP7/TAP2 downregulation) that may contribute to the failure of T lymphocyte recognition during an immune response. The precise identification of the molecular defects that underlie HLA class I abnormalities will have important implications for patients receiving T-cell-based specific immunotherapy. 
of the MHC class I antigen processing machinery (APM) (4, 5) .
Abnormalities in MHC class I surface expression and loss of antigen processing function have frequently been identified in murine (6) and human malignant cells (7) (8) (9) , and have also been associated with tumor progression in melanoma, colorectal cancer and breast carcinoma (7) (8) (9) . Molecular characterization of the antigen processing machinery complex has provided new tools to elucidate how tumors evade immune recognition. Studies using cultured tumor cell lines, antigen processing mutants and surgically removed malignant lesions demonstrated that loss or dysfunction of the proteasome subunits and the transporter associated with antigen processing (TAP) genes appear to contribute to deficient MHC class I surface expression (10) (11) (12) . In a panel of human tumors of distinct histology (13, 14) , loss or reduced expression and function of TAP and/or low molecular weight protein (LMP) were associated with impaired processing and presentation of antigenic peptides to CD8 þ cytotoxic lymphocytes (CTL), resulting in low levels or loss of MHC class I and resistance to CTL-mediated lysis (7) . These deficiencies in the antigen processing pathway could be reverted by cytokine treatment, particularly by IFNg (15, 16) .
Likewise, disturbance of the APM and MHC class I antigen dysregulation or loss can result from lack of b 2 m (b 2 -microglobulin) expression due to downregulation (9) or mutation in one allele and loss of heterozygosity (LOH) in the second allele (17, 18) . Furthermore, around 10-15% of colorectal tumors display MHC class I antigen loss (phenotype I) (19) Reduced expression correlated with a mutation in one allele of b 2 m, whereas loss of expression was seen in instances where a line was homozygous for one mutation or heterozygous for two mutations (8, 23) .
The mechanisms underlying HLA class I antigen loss have been predominantly studied in cultured tumor cell lines, in which molecular genetic analyzes are easier to accomplish, or in non-microdissected human tumors with contaminating DNA from the tissue surrounding the tumor cell (14, 22 
Materials and methods

Selection of patients and tumor samples by immunohistochemistry
A total of 124 patients diagnosed with colorectal carcinoma were selected to study loss of HLA. Samples of tumor tissues were provided by the Department of Surgery, Virgen de las Nieves University Hospital in Granada.
Sections of frozen tumor tissues 5-8 mm thick were cut on a microtome-cryostat (Bright), allowed to dry at room temperature for 
MSI analysis
DNA obtained from tumor samples and normal mucosa was analyzed for MSI using four mononucleotide repeat sequences. BAT-26
and BAT-40 are both polyadenine mononucleotide repeats; BAT-RII is a 10-bp polyadenine repeat within the coding region of the transforming growth factor-b type II receptor (TGFb-RII). We also used a tract of eight consecutive guanosines in the third exon of the BAX gene (26) . To amplify these microsatellite markers, the 5 0 end of one primer of each primer set was tagged with a fluorescent label (Applied Biosystems). Microsatellite instability was determined using the ABI-PRISM 310 DNA sequencer and Genescan 3.1 software (Applied Biosystems). The tumors that were positive in this initial step were later studied using DNA from microdissected tissue samples.
The primers used to amplify microsatellite markers were as Table 1 shows the HLA-A, B and C-negative tumors detected. The frequency of total loss was similar to that described in a previous study (19) . 
Results
Analysis of HLA class I antigen expression in colorectal tumors
LMP7 downregulation is a common event in MSI negative/ HLA-A, B and C -colorectal tumors
RT-PCR analysis of HLA-heavy chain, TAP1, TAP2, LMP2 and LMP7 was also used in the group of tumors that exhibited an HLA-A, B or C-negative phenotype. Table 1 We found specific downregulation of the components of the APM.
Whereas TAP1 expression was detected in 100% of colorectal tumors, TAP2 was not detected in 40% of cases. TAP genes are involved in the transport of peptides into the reticulum, and their downregulation is responsible for the lack of expression of HLA class I on the membrane surface (28) . The mechanism involved in these cases may explain the lack of expression in four of 10 tumor samples.
Additionally, transcription of the LMP7 gene was absent in nine of 10 tumor tissue samples compared with their normal mucosa counterpart (Fig. 2) . This finding reveals the importance of this protein in producing antigenic peptides that stabilize the structure of the heavy chain and permit its surface expression (29) .
We have no explanation for the mechanism that underlies HLA class I antigen loss in tumor CO5. As CO5 was MSI negative and HC-10 mAb-positive, we surmise that it has no alterations in the Table 1 Analysis of MSI-positive cases in negative HLA-ABC colorectal carcinomas
ND ¼ not determined *Microdissection studies showed that the wild-type allele coexisted with the mutated allele. Table 3 Cabrera 
Discussion
In this study we illustrate two major mechanisms that explain the lack of expression of HLA-A, B and C molecules in colorectal tumors: The functional consequences of these molecular defects may also differ in both groups of tumors. In fact, whereas TAP or LMP downregulation is often restored by IFN-g treatment (14) , structural defects cannot be overcome and can have a negative impact on the outcome of T cell-based immunotherapy (14, 18) . We cannot rule out however, the 
